ESTRO 2024 - Abstract Book

S1546

Clinical - Lower GI

ESTRO 2024

The findings of this study underscore the potential of HIF-1α as a valuable prognostic factor. Overexpression of HIF-1α may signify the presence of a more aggressive biological profile in anal squamous cell cancer (ASCC), suggesting a need for a correspondingly vigorous and tailored approach to its management.

Keywords: ASCC, Biomarker

References:

1. Robert Koch Institute. Cancer in Germany Cancer in Germany. 2014;

2. Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY. Hypoxia-Inducible Factors and Cancer. Curr sleep Med reports [Internet]. 2017 Mar 1;3(1):1.

3. Mohamed AA, Schlenter M, Heinzel A, Kintsler S, Eble M. Intensity-modulated radiotherapy associated with improved survival outcome in anal cancer. Front Oncol. 1AD;0:2566.

4. Mohamed AA, Risse K, Stock J, Heinzel A, Mottaghy FM, Bruners P, Eble MJ. Body Composition as a Predictor of the Survival in Anal Cancer. Cancers 2022, Vol 14, Page 4521 . 2022 Sep 18;14(18):4521.

2479

Digital Poster

Results of mono-institutional experience in liver metastases treated with stereotactic radiotherapy

Najla Slim 1 , Miriam Torrisi 2 , Marco Castellano 1 , Paolo Passoni 1 , Andrei Fodor 1 , Chiara Deantoni 1 , Martina Midulla 1 , Laura Giannini 1 , Roberta Tummineri 1 , Lucia Perna 3 , Sara Broggi 3 , Claudio Fiorino 3 , Antonella Del Vecchio 3 , Stefano Arcangeli 4 , Nadia Di Muzio 1,5 1 IRCCS ospedale San Raffaele, Radiation Oncology, Milano, Italy. 2 IRCCS ospedale San Raffaele, Radiation Oncology, Milano, Jamaica. 3 IRCCS ospedale San Raffaele, Medical Physics, Milano, Italy. 4 IRCCS San Gerardo dei Tintori, Radiation Oncology, Monza, Italy. 5 Vita-Salute San Raffaele Unuversity, Radiation Oncology, Milano, Italy

Purpose/Objective:

To report our results in patients (pts) with liver metastases treated with Stereotactic Ablative Radiotherapy (SABR).

Material/Methods:

All pts treated from 04/2016-04/2023 in our institution with SABR for liver metastases were retrospectively analyzed. Radiotherapy was delivered with Helical Tomotherapy (HT) or CyberKnife (CK). All pts underwent contrast-enhanced (ce) CT scan for simulation. A median number of 4 (3-8) fiducials were implanted before simulation for pts treated with CK. Overall survival (OS) and Local Relapse Free Survival (LRFS) were estimated with Kaplan-Meyer method. Toxicity was registered with CTCAE v5.0.